TITLE

Humoral and Cell-Mediated Immune Responses in Children and Adults after 1 and 2 Doses of Varicella Vaccine

AUTHOR(S)
Watson, Barbara
PUB. DATE
March 2008
SOURCE
Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS143
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Humoral and cell-mediated immune responses to varicella-zoster virus (VZV) have been evaluated after 1 and 2 doses of live attenuated varicella vaccine, Oka strain, in several studies. One dose of varicella vaccine, however, elicits detectable immune responses that are low and, in some cases, may be insufficient for complete protection against the virus after the normal decline in humoral and cell-mediated immunity with time. In contrast, immune responses after 2 doses are significantly higher and approximate the levels seen after natural disease. These investigations of vaccine-induced immunity suggest that 2 doses of VZV vaccine will better achieve the goals of the VZV vaccination program, by reducing the VZV burden of disease in childhood and preventing accumulation of young adults who are susceptible to or only partially protected from varicella.
ACCESSION #
31645385

 

Related Articles

  • Use and Limitations of Varicella-Zoster Virus—Specific Serological Testing to Evaluate Breakthrough Disease in Vaccinees and to Screen for Susceptibility to Varicella. Breuer, Judith; Schmid, D. Scott; Gershon, Anne A. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS147 

    A plethora of tests for determining the presence of antibodies to varicella-zoster virus (VZV) have been developed over the years, with a wide range of performance standards. There is general agreement that the presence of VZV antibodies in serum indicates immunity to varicella and protection...

  • Development of Varicella Vaccine. Takahashi, Michiaki; Asano, Yoshizo; Kamiya, Hitoshi; Baba, Koichi; Ozaki, Takao; Otsuka, Terumasa; Yamanishi, Koichi // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS41 

    The Oka strain of varicella-zoster virus (VZV) was first isolated from vesicles of an otherwise healthy 3-year- old boy with typical varicella. The virus was passaged 11 times in human embryonic lung fibroblasts at 34°C and 12 times in guinea pig embryo fibroblasts (GPEFs) at 37°C. GPEFs...

  • Varicella Immunogenicity with 1- and 2-Dose Regimens of Measles-Mumps-Rubella-Varicella Vaccine. Shinefield, Henry R.; Black, Steve; Kuter, Barbara J. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS152 

    A quadrivalent vaccine combining measles, mumps, rubella, and varicella antigens (MMRV) was developed to increase the coverage of varicella vaccine and reduce the number of injections children receive. Although the varicella antigen is as immunogenic in the latest formulation of MMRV vaccine as...

  • An Economic Analysis of the Universal Varicella Vaccination Program in the United States. Fangjun Zhou; Ortega-Sanchez, Ismael R.; Guris, Dalya; Shefer, Abigail; Lieu, Tracy; Seward, Jane F. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS156 

    Frequent varicella outbreaks with sizable impact on the US public health system have continued to occur despite the success of the country's 1-dose varicella vaccination program. The Advisory Committee on Immunization Practices recently recommended adding a routine second dose of varicella...

  • Perspective on Live Varicella Vaccine. Gershon, Anne A.; Katz, Samuel L. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS242 

    The attenuation of varicella-zoster virus (VZV) by Takahashi in 1974 was a remarkable achievement. It swiftly led to development of a live vaccine against chickenpox, which was initially tested in Japan. With its successful employment in immunocompromised children to prevent morbidity and...

  • Varicella Vaccine Effectiveness in the US Vaccination Program: A Review. Seward, Jane F.; Mann, Mona; Vázquez, Marietta // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS82 

    Varicella vaccine (Varivax, Merck) has been available in the United States since 1995. We reviewed published results of postlicensure studies of vaccine effectiveness. Among 19 studies, 17 reported on the effectiveness of vaccine received before exposure, and 2 reported on effectiveness after...

  • Varicella Vaccination of Immunocompromised Children. Levin, Myron J. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS200 

    Background. Exposure of immunocompromised children to varicella often requires postexposure prophylaxis. Exposures requiring this management are often not recognized. Varicella can he a severe disease when it occurs in immunocompromised children, in spite of antiviral therapy. Varicella exposure...

  • Influence of Age and Nature of Primary Infection on Varicella-Zoster Virus-Specific Cell-Mediated Immune Responses. Weinberg, Adriana; Lazar, Ann A.; Zerbe, Gary O.; Hayward, Anthony R.; Chan, Ivan S. F.; Rupert Vessey,6; Silber, Jeffrey L.; MacGregor, Rob R.; Chan, Kenny; Gershon, Anne A.; Levin, Myron J. // Journal of Infectious Diseases;4/1/2010, Vol. 201 Issue 7, p1024 

    Background. Varicella-zoster virus (VZV)-specific cell-mediated immunity is important for protection against VZV disease. We studied the relationship between VZV cell-mediated immunity and age after varicella or VZV vaccination in healthy and human immunodeficiency virus (HIV)-infected...

  • Vaccination against Herpes Zoster and Postherpetic Neuralgia. Oxman, Michael N.; Levin, Myron J. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS228 

    Background. Herpes zoster (HZ) and postherpetic neuralgia (PHN) cause significant morbidity in older adults. The incidence and severity of HZ and PHN increase with age in association with an age-related decline in varicella-zoster virus (VZV)-specific cell-mediated immunity (VZV-CMI). VZV...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics